PROBONEWFOOD. Investigación industrial para la obtención de nuevas fuentes proteicas alternativas, sostenibles, nutritivas y trazables a través de bioprocesos mediante el uso de IA

Details

Published on Wednesday, 29 March 2023 09:55

PROBONEWFOOD. Investigación industrial para la obtención de nuevas fuentes proteicas mediante uso de IA.

Proyecto concedido al amparo del “Programa Misiones de Ciencia e Innovación", del Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023, en el marco del Plan de Recuperación, Transformación y Resiliencia – Financiado por la Unión Europea – NextGenerationEU.

Proyecto: “PROBONEWFOOD - INVESTIGACIÓN INDUSTRIAL PARA LA OBTENCIÓN DE NUEVAS FUENTES PROTEICAS ALTERNATIVAS, SOSTENIBLES, NUTRITIVAS Y TRAZABLES A TRAVÉS DE BIOPROCESOS MEDIANTE USO DE IA.”

Expediente: MIG-20221025

Fecha concesión: 30 de Diciembre de 2022

Objetivo: PROBONEWFOOD es un proyecto de investigación industrial orientado a generar una base de conocimiento y tecnología aplicables en la búsqueda de nuevos modelos de alimentación humana más sostenibles en el uso de recursos y más respetuosos con el medio ambiente. Este proyecto pretende establecer fundamentos sólidos para la producción industrial de fuentes accesibles de proteínas alternativas, mediante el uso de herramientas biotecnológicas. Además, se monitorizarán las variables claves de los distintos procesos y se aplicarán modelos predictivos basados en inteligencia artificial (Machine Learning – Deep Learning).

Miembros del consorcio:

• JORGE S.L.
• AGRENVEC, S.L.
• EBERS MEDICAL TECHNOLOGY S.L.
• IASAPIENS INNOVATION S.L.
• VISCOFAN ESPAÑA S.L.

Proyecto subvencionado por el Centro para el Desarrollo Técnico e Industrial (CDTI), el Ministerio de Ciencia e Innovación, y la Unión Europea.

EBERS successfully overcomes Phase II of a pre-commercial procurement contract for the development of innovative solutions in the field of organ preservation

Details

Published on Tuesday, 07 March 2023 17:21

EBERS received on the 27^th of January the outcome of the evaluation of Phase 2 of the Pre-Commercial Procurement Contract for the Development of Innovative Solutions in the Field of Organ Preservation, signed with the Spanish Center for the Technological Development and Innovation (CDTI). The goal of this contract is the design and development of an ex vivo preservation system for solid organs beyond the state of the start, which can contribute to expand the organ donor pool for transplantation and reduce costs of healthcare systems. The works are being executed by EBERS in collaboration with Moses Products, a company specialized in plastic transformation, and Intraven, an SME specialized in the assembly, packaging and sterilization of medical devices.

Phase 2 of the project was devoted to the development of the prototype and the execution of a set of pilot tests. The works in this phase have lasted since the 1^st of October of 2021 until the 31^st of December of 2022 and have included the fabrication of a prototype of a new normothermic perfusion machine meeting the requirements of the contract and the execution of animal and non-animal tests with it. The evaluation of Phase 2 has been satisfactory and successful, meaning that the project passes to Phase 3, where the prototype will be validated in a pre-operational environment at the facilities of the Minimally Invasive Surgery Centre “Jesús Usón” in Cáceres, Spain.

We summarize below the most relevant aspects of the contract:

• Name of the project: Compra pública precomercial para el desarrollo de soluciones innovadoras en el ámbito de la preservación de órganos (Expte. CPP 01/2021 AB).
• Place of execution: Cáceres/Zaragoza/Madrid
• Period of execution: June 2021-March 2023
• Budget: 2.4 M€.
• Co-funded by CDTI and FEDER: Project co-funded by the European Regional Development Fund (ERDF) in the framework of the 2014-2020 Pluri-Regional Operational Programme of Spain.
• Goal: Design and development of an ex vivo preservation system for solid organs beyond the state of the start, which can contribute to expand the organ donor pool for transplantation and reduce costs of healthcare systems.

EBERS IN VII INTERNATIONAL WORKSHOP ON DCD DONORS

Details

Published on Friday, 20 January 2023 11:27

Las October 2022, EBERS CTO Víctor Alastrué attended to the VII INTERNATIONAL WORKSHOP ON DCD DONORS which took place la La Coruña (Spain), where the ARK kidney perfusion system was shown and live kidney and liver normothermic perfusions were carried out.

EIC Industry Day with Fresenius Kabi and Medtronic

Details

Published on Friday, 20 January 2023 11:13

EBERS was represented by its CEO, Pedro Moreo, in the Industry Day organized by the European Innovation Council (EIC) in collaboration with Fresenius Kabi and Medtronic. The meeting gathered more than 20 innovative European companies, which had the opportunity to present their technology and interact with representatives of the two multinationals. The event took place in November 2022 in Fresenius headquarters located in Bad Homburg, Germany.